169 related articles for article (PubMed ID: 35899380)
1. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
Lin LA; Zhang L; Kim HM; Frost MC
Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
[TBL] [Abstract][Full Text] [Related]
2. Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
Frost MC; Zhang L; Kim HM; Lin LA
JAMA Netw Open; 2022 Oct; 5(10):e2236298. PubMed ID: 36223118
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
4. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.
Lin LA; Fortney JC; Bohnert ASB; Coughlin LN; Zhang L; Piette JD
J Subst Abuse Treat; 2022 Feb; 133():108492. PubMed ID: 34175175
[TBL] [Abstract][Full Text] [Related]
5. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
[TBL] [Abstract][Full Text] [Related]
7. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
8. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
9. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
Textor L; Ventricelli D; Aronowitz SV
Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
[TBL] [Abstract][Full Text] [Related]
10. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
11. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
[TBL] [Abstract][Full Text] [Related]
12. Telehealth Utilization Is Associated with Lower Risk of Discontinuation of Buprenorphine: a Retrospective Cohort Study of US Veterans.
Vakkalanka JP; Lund BC; Ward MM; Arndt S; Field RW; Charlton M; Carnahan RM
J Gen Intern Med; 2022 May; 37(7):1610-1618. PubMed ID: 34159547
[TBL] [Abstract][Full Text] [Related]
13. The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration.
Perumalswami PV; Kilpatrick S; Frost MC; Adams MA; Kim HM; Zhang L; Lin L
Addiction; 2023 Jun; 118(6):1062-1071. PubMed ID: 36738085
[TBL] [Abstract][Full Text] [Related]
14. Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes.
Nguyen B; Zhao C; Bailly E; Chi W
J Gen Intern Med; 2024 Jan; 39(1):95-102. PubMed ID: 37670069
[TBL] [Abstract][Full Text] [Related]
15. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
[TBL] [Abstract][Full Text] [Related]
16. A comparison of office-based buprenorphine treatment outcomes in Bronx community clinics before versus during the COVID-19 pandemic.
Cunningham CO; Khalid L; Deng Y; Torres-Lockhart K; Masyukova M; Thomas S; Zhang C; Lu T
J Subst Abuse Treat; 2022 Apr; 135():108641. PubMed ID: 34863608
[TBL] [Abstract][Full Text] [Related]
17. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
18. Utilizing telemedicine during COVID-19 pandemic for a low-threshold, street-based buprenorphine program.
Harris R; Rosecrans A; Zoltick M; Willman C; Saxton R; Cotterell M; Bell J; Blackwell I; Page KR
Drug Alcohol Depend; 2022 Jan; 230():109187. PubMed ID: 34890927
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
20. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
